Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

University of Leicester and University of Cambridge researchers found no significant difference in maternal weight change or ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

The findings showed that for women with gestational diabetes and a BMI ≥ 25 kg/m², incorporating a 1,200 kcal/day diet into ...

An early-morning rise in blood sugar is common in people with diabetes. Find out more about why it happens and how to prevent ...

Investigating how the production of insulin is regulated in fruit flies reveals surprising insights that may help to better understand how this process unfolds in humans.

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...

Merilog also marks the third insulin biosimilar approved in the United States, following two long-acting biosimilars approved in 2021. 1 "The FDA has now approved three biosimilar insulin products to ...

The rapid-acting insulin aspart biosimilar joins two prior long-acting insulin biosimilar products approved in 2021. Biosimilars are highly similar to already approved products and have no ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...